127 related articles for article (PubMed ID: 16554750)
1. Jak3 contributes to the activation of ALK and Stat3 in ALK(+) anaplastic large cell lymphoma.
Amin HM; Lin Q; Lai R
Lab Invest; 2006 Apr; 86(4):417-9; author reply 420-1. PubMed ID: 16554750
[No Abstract] [Full Text] [Related]
2. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.
Marzec M; Kasprzycka M; Ptasznik A; Wlodarski P; Zhang Q; Odum N; Wasik MA
Lab Invest; 2005 Dec; 85(12):1544-54. PubMed ID: 16170336
[TBL] [Abstract][Full Text] [Related]
3. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Han Y; Amin HM; Frantz C; Franko B; Lee J; Lin Q; Lai R
Leukemia; 2006 Sep; 20(9):1602-9. PubMed ID: 16871283
[TBL] [Abstract][Full Text] [Related]
4. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
[TBL] [Abstract][Full Text] [Related]
5. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.
Dien Bard J; Gelebart P; Anand M; Zak Z; Hegazy SA; Amin HM; Lai R
Am J Pathol; 2009 Aug; 175(2):825-34. PubMed ID: 19608866
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.
Zamo A; Chiarle R; Piva R; Howes J; Fan Y; Chilosi M; Levy DE; Inghirami G
Oncogene; 2002 Feb; 21(7):1038-47. PubMed ID: 11850821
[TBL] [Abstract][Full Text] [Related]
7. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
Han Y; Amin HM; Franko B; Frantz C; Shi X; Lai R
Blood; 2006 Oct; 108(8):2796-803. PubMed ID: 16825495
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma.
Amin HM; Medeiros LJ; Ma Y; Feretzaki M; Das P; Leventaki V; Rassidakis GZ; O'Connor SL; McDonnell TJ; Lai R
Oncogene; 2003 Aug; 22(35):5399-407. PubMed ID: 12934099
[TBL] [Abstract][Full Text] [Related]
9. Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma.
Cho-Vega JH; Rassidakis GZ; Amin HM; Tsioli P; Spurgers K; Remache YK; Vega F; Goy AH; Gilles F; Medeiros LJ
Leukemia; 2004 Nov; 18(11):1872-8. PubMed ID: 15385932
[TBL] [Abstract][Full Text] [Related]
10. Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma.
Lai R; Rassidakis GZ; Lin Q; Atwell C; Medeiros LJ; Amin HM
Hum Pathol; 2005 Sep; 36(9):939-44. PubMed ID: 16153455
[TBL] [Abstract][Full Text] [Related]
11. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
[TBL] [Abstract][Full Text] [Related]
12. β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Anand M; Lai R; Gelebart P
Haematologica; 2011 Feb; 96(2):253-61. PubMed ID: 20971814
[TBL] [Abstract][Full Text] [Related]
13. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
14. Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.
Marzec M; Halasa K; Liu X; Wang HY; Cheng M; Baldwin D; Tobias JW; Schuster SJ; Woetmann A; Zhang Q; Turner SD; Ødum N; Wasik MA
J Immunol; 2013 Dec; 191(12):6200-7. PubMed ID: 24218456
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
[TBL] [Abstract][Full Text] [Related]
16. STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.
Spaccarotella E; Pellegrino E; Ferracin M; Ferreri C; Cuccuru G; Liu C; Iqbal J; Cantarella D; Taulli R; Provero P; Di Cunto F; Medico E; Negrini M; Chan WC; Inghirami G; Piva R
Haematologica; 2014 Jan; 99(1):116-24. PubMed ID: 23975180
[TBL] [Abstract][Full Text] [Related]
17. JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells.
Shi X; Franko B; Frantz C; Amin HM; Lai R
Br J Haematol; 2006 Oct; 135(1):26-32. PubMed ID: 16939498
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
19. The anaplastic lymphoma kinase in the pathogenesis of cancer.
Chiarle R; Voena C; Ambrogio C; Piva R; Inghirami G
Nat Rev Cancer; 2008 Jan; 8(1):11-23. PubMed ID: 18097461
[TBL] [Abstract][Full Text] [Related]
20. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.
Kasprzycka M; Marzec M; Liu X; Zhang Q; Wasik MA
Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9964-9. PubMed ID: 16766651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
